WebGP

Rural GP in a small village on Crete, Greece.
Interested in public health, running and fitness, evolutionary psychology, social media, technology.

[WebGP @WebGP]

@EASOobesity @MEPObesityGroup @JerkovicRomana @EASOobesityECN @WHO_Europe @UNICEF @EU_Commission @EasoPresident @Europarl_EN @Adamowicz_Magda @KremlinKW @DianaCastill08 @ECPObesity

[EASO @EASOobesity]

Wonderful to join @MEPObesityGroup @JerkovicRomana and colleagues in Parliament
for a special focus on #obesity in childhood!

We are joined by MEPs and colleagues from EASO, @EASOobesityECN @WHO_Europe and @UNICEF

@EU_Commission

[Benjamin Bikman @BenBikmanPhD]

Retatrutide has an advantage over other GLP-1-based drugs, and I think it comes down to glucagon, one of the more overlooked hormones in metabolism.

Retatrutide adds glucagon on top of the GLP-1 and GIP signals. In the newly-released phase 3 TRIUMPH-1 trial, just published in NEJM (NCT05929066), adults with obesity took it for 80 weeks. At the top dose, people lost 25% of their body weight on average. More than a third lost at least 30%. Fasting insulin fell by more than half, something I always focus on, and over 90% of people with prediabetes ended up with normal blood sugar.

Insulin tells the body to store fuel, and glucagon tells the body to burn it. In a separate study, researchers raised glucagon to normal physiological levels and found that the liver's mitochondria burned fuel 50 to 75% faster (PMID 39197461). In another study, a glucagon infusion raised energy expenditure by about 15% (PMID 26434748).

Ideally, if you take it, protect your fat-free mass with resistance exercise and abundant protein and natural fats. I also feel strongly that any of these drugs needs to be viewed as a temporary crutch--use it to develop new habits (i.e., control carbs) and then taper off.

[Dr David Unwin @lowcarbGP]

Insulin resistance and its twin sister hyperinsulinaemia probably account for 80% of my work as a doctor It predates T2D by about 10 years Critically it responds to a low carb diet more than a low fat diet Please look at our review published here https://t.co/mrIAUmLFPR @BenBikmanPhD @BraciaRodzen @ketoproject1

[Benjamin Bikman @BenBikmanPhD]

Metabolic health benefits the most when insulin comes down the most.

A new clinical trial tested three popular diets, and the diet that lowered insulin the most delivered the greatest metabolic payoff.

Liver fat fell almost 50% more on the low-carb diet than on the others (low-fat plant-based and Mediterranean). The liver also became two to three times more insulin sensitive, produced less new fat from carbohydrate, and suppressed glucose production more effectively. Insulin across the day dropped far more with carbohydrate restriction, glucose fell more than twice as much, A1c improved the most, and prediabetes (i.e., insulin resistance) reversed at the highest rate.

That is the beneficial biochemistry of a lower-insulin state. When insulin falls, the liver is no longer pushed to make and store fat. Lipogenesis slows, glucagon can tell the liver to oxidize fat instead, and the tissue becomes more responsive to the insulin that remains. The body becomes more insulin sensitive, and the liver can finally burn the fat it has been holding.

Even though total weight loss was comparable across the three groups (by study design), lower insulin is what let the liver let go of the fat.

https://t.co/h6df347EDD

[EASO @EASOobesity]

Algorithm 2.0: EASO Pharmacological Framework for Obesity Management

✔️ Helps clinicians match pharmacological obesity management to an individual’s health needs, moving beyond weight loss alone to consider complications, mechanisms & treatment goals.

https://t.co/289FP5r93D

[EASO @EASOobesity]

EASO plays a pivotal role as a dissemination partner and in shaping the strategic direction and policy development across various EU-funded research projects, including Horizon 2020 and Horizon Europe initiatives.

https://t.co/mdboVMFIR6

[Scott Isaacs @scottisaacsmd]

MASH is a systemic immunometabolic network disorder. New commentary highlights how GLP‑1–based therapies modulate the cardio‑hepato‑renal axis reprogramming disease biology.
https://t.co/2fhf8i8qWt

[WebGP @WebGP]

@TheLancetEndo It’s already happening with the EASO framework 2.0

[American College of Cardiology @ACCinTouch]

The 2026 CKM Syndrome Guideline outlines the four stages of CKM syndrome, highlights major risk factors & provides comprehensive recommendations for screening, prevention & treatment. Check out the top 5️⃣ key takeaways 👇.

🔎 Learn more: https://t.co/151GI2RUYc #CardiologyMag

[Scott Isaacs @scottisaacsmd]

Higher BMI is linked to increased risk of at least 19 cancers across the body (and lower risk for a few).
https://t.co/zrt85TWDWC

[Today In History @historigins]

This video shows the opening ceremony of the 2004 Summer Olympics in Athens, Greece, which marked the return of the Games to their historic birthplace. The ceremony combined theatrical performances, Greek cultural heritage, and a display of sporting unity, as thousands of athletes from 201 delegations made their entrance into the stadium. ⁠
⁠
The lighting of the Olympic cauldron marked the official start of the Games and celebrated the enduring legacy of the Olympic Games in the modern era.⁠

[EASO @EASOobesity]

Lisa Buchanan presented at #ECO2026 in Istanbul: The Role of Trauma in Obesity

She discussed the "More Than Weight" report, which explored the human, social, and economic costs of obesity, alongside the critical link between obesity and trauma.

#ECO2026

[NICE @NICEComms]

New recommendation: Semaglutide (Wegovy) can now be prescribed to help protect the heart, not just to manage weight: https://t.co/BH4w1kI4So

It's for adults who've already had a heart attack, stroke, or cardiovascular event and have a BMI of 27 or above.

[EASO @EASOobesity]

The identification and prioritization of people at high risk for the complications of obesity could help to guide effective allocation of resources including pharmacological, dietary, behavioral or surgical interventions but is currently hindered by important challenges

https://t.co/2TnUPmqpTs @nature
HT @jasoncghalford

[Eric Topol @EricTopol]

Our best shot for preventing many diseases?
Exercise
A @Cell_Metabolism new review
https://t.co/axi6aUDpZ7

[American Heart Association @American_Heart]

The American Heart Association mourns the passing of the legendary cardiologist Eugene Braunwald, M.D., widely recognized as one of the most influential figures in the history of cardiovascular medicine. Over seven decades, his work reshaped the understanding and treatment of heart disease, leading many to call him the father of modern cardiology.

Braunwald was a lifelong contributor to the American Heart Association, helping advance its research and scientific mission, and was honored with some of the Association’s highest honors for his lasting influence on cardiovascular care and research. His influence extended well beyond his own discoveries, as generations of Association‑supported investigators, clinicians and academic leaders were trained by Braunwald or guided by the clinical trial standards and mentorship models he helped establish.

https://t.co/ieZuHYMyOP

[Sourbha Satish Dani, MD, MSc, FACC, FASE @SaurabhSDani]

The Hook
Cardiology trials keep telling you "20% risk reduction."
But what if that same trial meant:
→ 1 in 50 patients helped (NNT 50)
→ 49 of 50 got zero benefit
Welcome to the greatest trick in clinical trials: Relative Risk vs. Absolute Risk. A thread 🧵👇

[Iran Embassy in Indonesia @IraninIndonesia]

Trump announces he is "permanently opening" the Strait of Hormuz.